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Mucosal-associated invariant T (MAIT) cells are innate-like T cells that can detect bacteria-
derived metabolites presented on MR1. Here we show, using a controlled infection of humans
with live Salmonella enterica serovar Paratyphi A, that MAIT cells are activated during
infection, an effect maintained even after antibiotic treatment. At the peak of infection MAIT
cell T-cell receptor (TCR)β clonotypes that are over-represented prior to infection transiently
contract. Select MAIT cell TCRβ clonotypes that expand after infection have stronger TCR-
dependent activation than do contracted clonotypes. Our results demonstrate that host
exposure to antigen may drive clonal expansion of MAIT cells with increased functional
avidity, suggesting a role for speciﬁc vaccination strategies to increase the frequency and
potency of MAIT cells to optimize effector function.
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Mucosal-associated invariant T (MAIT) cells are non-classical T cells with both innate and adaptive immuneproperties1. These cells respond to a recently identiﬁed
class of antigens, vitamin B metabolites derived from bacteria,
that are presented on the MHC class I-like molecule MR12. This
discovery, along with an abundance in humans3,4, conservation
across species5–7, and the defective immune response of MR1/
MAIT cell-deﬁcient mice to infection by Francisella tularensis8,
Klebsiella pneumoniae9, and Mycobacterium tuberculosis10, has
led to the notion that these cells have an important function in
controlling bacterial infections.
MAIT cells recognize vitamin metabolites due to their T-cell
receptor (TCR) usage, which in humans is an invariant TCRα
chain TRAV1-2–TRAJ33 (or TRAJ12/TRAJ20 at lower fre-
quencies)11. However, their TCRβ chain usage is oligoclonal, with
predominantly TRBV20 and TRBV6 usage12. Such varied TCRβ
chain usage has been suggested to enable differential antigen, and
potentially pathogen, recognition13–15.
Most studies of MAIT cells in bacterial infection have been
either in vitro10,16,17 or in vivo mouse models10,8,18. These studies
have demonstrated that MAIT cells respond to bacteria through
upregulation of activation markers and proinﬂammatory cytokine
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Fig. 1MAIT cell frequency and phenotype during S. Paratyphi A infection. a Outline of the blood sampling protocol for the controlled human S. Paratyphi A
infection. PBMCs were isolated at various time points from 25 individuals challenged with live S. Paratyphi A and analyzed by ﬂow cytometry. Graphs
showing the frequency of MAIT cells in the CD3+ T-cell compartment represented as fold change from baseline in individuals b not diagnosed (n= 8) or c
diagnosed with enteric fever (n= 17). Graphs showing the percentage of activated MAIT cells in challenged individuals d not diagnosed and e diagnosed
with enteric fever analyzed by expression of CD38. Each symbol represents a participant and a key for diagnosed individual identiﬁcation is provided. For
diagnosed individuals, infection was diagnosed between day 4 and day 7, with black symbols representing samples collected prior to diagnosis and red
symbols representing samples taken on/after diagnosis. Line indicates mean and error bars represent standard error of the mean (SEM). Statistical
signiﬁcance was calculated using one-way analysis of variance (ANOVA) with Dunnett’s test, where *P< 0.05 and ***P< 0.001. PT, S. Paratyphi A
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production, and only in response to bacteria that contain the
riboﬂavin synthesis pathway16,18, which provide a source of sti-
mulatory vitamin B metabolites. These ﬁndings are important, as
MAIT cells can also become activated in an MR1-independent
manner through cytokine stimulation19,20. Collectively, these
studies suggest that the presence of the ligand is important for
MAIT cell response to bacterial infection.
Most of the few human studies of MAIT cells are cross-sec-
tional, requiring comparison to age-matched healthy
controls16,21,22. The only longitudinal studies of MAIT cells in
response to bacterial infection involve the challenge of human
volunteers with live attenuated Shigella17, live Salmonella enterica
serovar Typhi23, and infection of non-human primates with M.
tuberculosis24. Although these studies describe changes in the
frequency and activation of MAIT cells, the TCR repertoire sta-
bility and clonal response of MAIT cells is yet to be explored.
To address this deﬁcit, here we utilize samples from a con-
trolled human infection model of live S. enterica serovar
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Fig. 2 MAIT cell TCRβ usage is oligoclonal during enteric fever. MAIT cells were sorted from frozen PBMCs from six individuals challenged with S.
Paratyphi A and diagnosed with enteric fever (pre-, mid-, and post-infection) and the TCRβ usage analyzed. a Pie charts of TRBV usage from diagnosed
individuals. The weighted b TRBV and c TRBJ usage proﬁle for diagnosed individuals shown as a heatmap with hierarchical clustering performed using
Euclidean distance. Lower x-axis labels indicate diagnosed individual donors 1–6. Top x-axis color bars indicate sample time point
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Paratyphi A25, which allows us to study the dynamic and clonal
response of MAIT cells during a human invasive bacterial
infection. We show that the frequency of MAIT cells decreases
prior to the diagnosis of enteric fever. MAIT cells in these diag-
nosed individuals become activated at the peak of infection and
maintain this activation, even with antibiotic treatment. TCR
analysis reveals that the MAIT cell TCRβ repertoire undergoes
reshaping with evidence of clonal expansion and contraction.
Assessment of the speciﬁc TCRβ clonotypes suggests that one of
the factors modulating the expansion of select clonotypes could
be the higher functional avidity of their TCRβ to the bacterial
metabolite antigen. Our results enhance our understanding of the
MAIT cell clonal response and TCR repertoire during human
bacterial infections.
Results
MAIT cells decrease in frequency during enteric fever. We
analyzed the relative frequency of circulating Vα7.2+ CD161+
MAIT cells over time in 25 healthy individuals challenged with
live S. Paratyphi A. The MAIT cell ﬂow cytometry/cell sorting
gating strategy is outlined in Supplementary Fig. 1. Staining with
MR1 tetramers26 has provided conclusive evidence conﬁrming
the identity of circulating Vα7.2+ CD161+ MAIT cells, as shown
in Supplementary Fig. 2. An overview of the human challenge
trial and blood sampling protocol is shown in Fig. 1a. The fre-
quency of MAIT cells was relatively stable in individuals not
diagnosed with infection (Fig. 1b), with no signiﬁcant differences
(P> 0.05) measured by one-way analysis of variance (ANOVA)
with Dunnett’s test. By contrast, there was an early decrease in the
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Fig. 3 The over-represented MAIT cell clonotypes undergo transient contraction during enteric fever. MAIT cells were sorted from frozen PBMCs from six
individuals challenged with S. Paratyphi A and diagnosed with enteric fever (pre-, mid-, and post-infection) and the TCRβ repertoire analyzed. MAIT cells
from healthy individuals sampled twice (21 days apart) were analyzed as a control. a Examples of clonotype abundance scatterplots for a healthy and a
diagnosed (donor 1) individual. Scatterplot axes represent log10 clonotype frequencies in each sample (overlapping clonotypes only) and point size is
scaled to the geometric mean of the clonotype frequency in both sample time points. b Example graphs of the occupied homeostatic space of MAIT cell
clonotypes in a healthy and diagnosed (donor 1) individual. Measured as a proportion taken up by over-represented (0.05–1), large (0.01–0.05), medium
(0.001–0.01), and small (0–0.001) clonotypes. c Summary graphs of occupied homeostatic space taken up by MAIT clonotypes in diagnosed donor 1–6.
Line is the mean with error bars representing SEM. Each symbol represents one individual and a key is provided for identiﬁcation. Statistical signiﬁcance
was calculated using Student’s paired two-tailed t-test, where *P< 0.05
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frequency of MAIT cells prior to diagnosis of enteric fever to 0.88
± 0.04 on day 4, which decreased signiﬁcantly to 0.63± 0.06
7–8 days after challenge (Fig. 1c). The frequency of MAIT cells in
the diagnosed individuals then recovered after antibiotic treat-
ment (day 28) and, in the majority (59%) of challenged indivi-
duals, we observed an increase in frequency from baseline.
MAIT cells are activated during enteric fever. We next exam-
ined the activation of circulating MAIT cells in challenged indi-
viduals by expression of CD38. There was no increase in the
expression of CD38 over time on MAIT cells from individuals
who were not diagnosed with enteric fever (Fig. 1d). In contrast,
the expression of CD38 was signiﬁcantly increased on 16.8± 4.2%
of MAIT cells 9–11 days after challenge in individuals that
developed enteric fever (Fig. 1e). This signiﬁcant upregulation of
CD38 was maintained, even following antibiotic treatment where
16.3± 2.5% of MAIT cells were still expressing CD38.
To further characterize the MAIT cell phenotype during
infection, mass cytometry analysis was performed on blood
samples from four diagnosed individuals. We found that
MAIT cells expressed the intracellular proliferation marker
Ki67 following diagnosis (Supplementary Fig. 3), similar to
observations made in previous bacterial and viral infection
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Fig. 4 MAIT clonotype composition is altered during enteric fever. MAIT cells were sorted from frozen PBMCs from individuals challenged with S.
Paratyphi A and diagnosed with enteric fever (pre-, mid-, and post-infection) and the TCRβ repertoire analyzed. a Representative clonotype tracking
heatmap for a diagnosed individual (donor 1) showing top 100 clonotypes with hierarchical clustering on the left y-axis and the CDR3β sequences on the
right y-axis. b Example shared clonotype abundance plots for diagnosed donor 1 and donor 4. The top ﬁve clonotypes shared pre- and post-infection are
displayed. Orange indicates expanded clone (≥2-fold increase), blue indicates contracted clone (≥2-fold decrease) and yellow indicates a stable clone. c
Graph summarizing the clonotype abundance plots, showing the proportion of the top ﬁve clones undergoing either contraction/expansion over time in
healthy controls (n= 3) and diagnosed individuals (n= 6). Bars plotted as mean with error bars representing SEM. Statistical signiﬁcance calculated using
Student’s unpaired two-tailed t-test where *P< 0.05
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studies23,27. This increased expression at the peak of infection was
conﬁrmed by ﬂow cytometry on six additional diagnosed
individuals, showing that 18.6± 6.6% of activated (CD38+)
MAIT cells expressed Ki67 at the peak of infection compared
to 5.5± 2.0% of non-activated (CD38−) MAIT cells (Supplemen-
tary Fig. 4). Interestingly, very few Ki67+ cells were observed
following antibiotic treatment, although 27.7± 8.0% of
MAIT cells still retained CD38 expression (Supplementary Fig. 4).
Additional analysis of surface markers revealed no substantial
differences in the expression of additional activation markers or
tissue-homing markers between CD38+Ki67+and CD38−Ki67−
cells at the peak of infection (Supplementary Fig. 3).
Together, the decreased frequency and acquisition of an
activated and proliferating phenotype suggests that circulating
MAIT cells in individuals diagnosed with enteric fever are
responding to the presence of S. Paratyphi A.
MAIT cell TCRβ usage remains oligoclonal during enteric
fever. In vitro experiments to study the activation of MAIT cells
isolated from healthy volunteers indicated that activation was
partially antigen-dependent as addition of MR1 blocking anti-
body could partially reduce the MAIT cell response to S. Para-
typhi A infection (Supplementary Fig. 5). The MAIT cell
activation response to S. Paratyphi A was also partially IL-12-
dependent, and a combination of both MR1 and IL-12p40
blocking antibodies prevented MAIT cell activation (Supple-
mentary Fig. 5). This suggested that MAIT cell in vitro response
was not only driven by antigen recognition, but also by cytokine-
dependent activation.
We analyzed the TCRβ repertoire of six individuals challenged
with S. Paratyphi A and diagnosed with enteric fever to determine
whether the MAIT cell response in vivo was TCR-dependent, and
therefore potentially antigen-driven. Consistent with previous
ﬁndings11,12, we found the TRBV usage of MAIT cells was
oligoclonal, characterized by the preferential use of TRBV20 and
TRBV6 in all diagnosed individuals, with inter-donor variation
ranging from 31 to 84% of the total chain usage (Fig. 2a, b). This
oligoclonality was maintained during infection and was also
evident to a lesser extent in the TRBJ usage (Fig. 2c). This is
similar to the TCRβ chain usage observed in healthy (not
challenged, control) individuals over time (Supplementary Fig. 6).
These results indicate that the TCRβ usage by MAIT cells is not
inﬂuenced by the presence of S. Paratyphi A and that if changes
were occurring in MAIT TCRβ repertoire that it would be on the
clonotypic level.
Over-represented MAIT cell clonotypes contract mid-infection.
To determine whether changes were occurring in MAIT cells at
the clonotypic level, we analyzed circulating MAIT cell clonotypes
based on the CDR3β sequences in six diagnosed individuals. In
keeping with the ﬁndings of Lepore et al.12, we conﬁrmed that the
MAIT cell clonotypes were stable over time, shown by the
example clonotype scatterplot of a healthy control individual
(Fig. 3a). However, MAIT cells in the diagnosed individual pre-
and post-infection scatterplot appear less stable over time.
To explore this further, we analyzed the clonal space home-
ostasis of MAIT cell clonotypes over time to understand whether
the distribution of the clonotypes underwent changes in response
to infection. In a healthy control individual, the clonal
distribution was relatively stable over time. In contrast, when
we analyzed the clonal distribution in a diagnosed individual
(donor 1), we observed marked changes, particularly in the
proportion of space used by the over-represented MAIT cell
clonotypes (Fig. 3b). When comparing the clonal distribution in
all diagnosed individuals, there was a signiﬁcant decrease in the
proportion of over-represented clones from 0.17± 0.05 at base-
line to 0.10± 0.04 mid-infection, but there was no signiﬁcant
difference between the baseline and post-infection (Fig. 3c). There
were also no signiﬁcant changes to the MAIT cell clonal
distribution in the undiagnosed individuals (Supplementary
Fig. 7). These results demonstrate that changes to MAIT cell
clonotypes in response to infection occur most notably to those
that are over-represented.
MAIT cells clonotype composition alters during enteric fever.
To determine whether the over-represented MAIT cell clonotypes
following infection were different to those present before infec-
tion, we analyzed the circulating MAIT cell clonotype composi-
tion based on the CDR3β sequence in six diagnosed individuals.
An example clonotype tracking heatmap for a diagnosed indivi-
dual (donor 1) shows that the clonotypes present at high fre-
quency following infection were not the same clonotypes that
were at high frequency before infection (Fig. 4a). A shared clo-
notype abundance plot with the top ﬁve clonotypes displayed for
two diagnosed individuals shows clonal expansion and contrac-
tion occurring, with a predominating clonotype present post-
infection in individual donor 1 (Fig. 4b). Shared clonotype
abundance plots for all diagnosed individuals are shown in
Supplementary Fig. 8. When comparing the top ﬁve clones across
all diagnosed individuals, we observed signiﬁcantly greater pro-
portion of top clonotypes undergoing clonal expansion/contrac-
tion (0.53± 0.11) compared to healthy controls (0.13± 0.07)
(Fig. 4c). These results demonstrate that the composition of
MAIT cell clonotypes in circulation changes in response to S.
Paratyphi A infection.
Expanded MAIT cell TCRβ clonotypes have greater activation.
To investigate whether the MAIT cell TCRβ clonotypes that
expanded in diagnosed individuals in response to S. Paratyphi A
conveyed a functional advantage in their response to antigen, we
generated an in vitro model by transducing JRT3 cells with len-
tiviral vectors containing MAIT cell TCR sequences of interest.
We produced lines expressing the most common MAIT TCRα
chain TRAV1-2–TRAJ33 (Supplementary Fig. 9) and the MAIT
cell TCRβ clonotypes selected from donor 1 and donor 3. The
clonotypes chosen were those that had expanded from pre- to
post-infection by a large fold-change and compared this with a
clonotype that had contracted by a large fold-change and used the
most common TCRβ chain (TRBV20-1). We tested their acti-
vation in response to bacterial supernatant and riboﬂavin meta-
bolite ligands. Details of the TCRβ clonotypes selected are
Table 1 TCRβ clonotypes used for Jurkat.MAIT production
Donor TRBV TRBD TRBJ Clone CDR3β sequence Frequency pre-infection Frequency post-infection Classiﬁcation
Donor 1 6-1 2 2–3 CASSETSGSPDTQYF 1.21% 21.1% Expanded
20-1 1/2 2–7 CSASPRGRDLPEQYF 3.4% 0.02% Contracted
Donor 3 6-4 2 2–1 CASSDGTSDEQFF 0.01% 1.3% Expanded
20-1 2 2–7 CSARQRDYEQYF 1.8% 0.01% Contracted
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presented in Table 1. The Jurkat.MAIT gating strategy, Vα7.2
expression and CD3 mean ﬂuorescence intensity (MFI) overlay
(ensuring comparable levels of surface TCR across the Jurkat.
MAIT line pairs) are shown in Supplementary Figs. 10 and 11,
respectively.
Escherichia coli has been previously shown to produce MAIT
cell-activating ligands through the riboﬂavin synthesis pathway26.
As S. Paratyphi A also contains the riboﬂavin synthesis pathway
they would be expected to also produce MAIT cell-activating
ligands. In response to either S. Paratyphi A or E. coli overnight
culture supernatant, the expanded TCRβ clonotypes showed
greater activation compared to the contracted clonotypes (Fig. 5a).
All lines displayed a dose-dependent response and their activation
could be completely blocked with the use of an MR1 blocking
antibody (Supplementary Fig. 12). This suggests that the
expanded TCRβ clonotypes have greater activation, but this is
not an exclusive response to S. Paratyphi A, as the clonotypes do
not convey preferential speciﬁcity between the different bacteria.
To investigate whether the extent of Jurkat.MAIT activation to
bacterial supernatant by the different TCRβ clonotypes correlated
to their activation by stimulatory riboﬂavin metabolite ligands, we
stimulated these cells with the strong precursor MAIT ligand 5-
amino-6-(D-ribitylamino)uracil (5-A-RU) plus methylglyoxal and
the weaker ligand 6,7-dimethylribityl lumazine (RL-6,7-DiMe)
(Fig. 5a). Both lines showed a dose-dependent and MR1-driven
response to the ligands (Supplementary Fig. 13). However, the
expanded TCRβ clonotypes showed a greater activation overall by
both ligands when compared to the contracted clonotype,
particularly for donor 1 (which was further conﬁrmed by
studying the rate of dissociation of 5-(2-oxopropylideneamino)-
6-D-ribitylaminouracil (5-OP-RU) MR1 tetramers bound to
Jurkat.MAIT lines in the presence of excess anti-MR1 blocking
antibody, shown in Supplementary Fig. 14). This pattern of
activation reﬂects what we observed in the bacterial supernatant
experiments, suggesting that the riboﬂavin derivatives were the
primary antigen that the Jurkat.MAIT lines were responding to in
the bacterial supernatant.
When co-culturing the Jurkat.MAIT lines with C1R.MR1 cells
without addition of bacteria or ligand, we observed CD69
expression on the expanded Jurkat.MAIT line from donor 1 was
ﬁvefold higher compared to when cultured alone (Fig. 5b). This
baseline activation, that can be blocked by MR1 blocking
antibody, suggests that this clonotype was activated by compo-
nents in the cell culture media. This was determined to be due to
the vitamin metabolites present in the FBS, as the use of dialyzed
FBS, which fails to alter activation of HLA-restricted T cells
(Supplementary Fig. 15), reduced this baseline response (Fig. 5c).
Together, these results suggest that certain MAIT cell
clonotypes may expand in response to infection due to their
greater functional avidity of their TCR to MAIT cell ligands.
Discussion
MAIT cells and their bacterial reactivity are conserved across
species, indicating their vital role in the host immune response to
bacterial infections6. In this study, we had a unique opportunity
to further our understanding of MAIT cells and their clonal
response in bacterial infections as we utilized samples from a
controlled human infection model of the invasive bacterial
pathogen S. Paratyphi A in healthy volunteers. This has provided
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Fig. 5 Greater activation of Jurkat.MAIT cells expressing TCRβ clonotypes expanded after enteric fever. Jurkat.MAIT cell lines expressing the TCRβ chain of
clonotypes that either expanded or contracted in diagnosed donor 1 and donor 3 were produced. Using C1R.MR1 cells as antigen-presenting cells, the
activation of Jurkat.MAIT lines was measured by ﬂow cytometry using the MFI of CD69 in response to in vitro bacterial supernatant and ligand stimulation
when co-cultured for 18–20 h. a Heatmap of CD69 expression on Jurkat.MAIT cell lines when co-cultured with 5 μL E. coli (EC) supernatant, 5 μL S.
Paratyphi A (PT) supernatant, 0.18 μM 5-amino-6-(D-ribitylamino)uracil (5-A-RU) with 10 μMmethylglyoxal (MG) and 75 μM 6,7-dimethylribityl lumazine
(RL-6,7-DiMe). b Baseline activation of Jurkat.MAIT cell lines when co-cultured without stimulus added and c with normal vs. dialyzed FBS. For blocking
experiments, 10 μg/mL of MR1 blocking antibody (aMR1) or IgG2a isotype control was added. Bars show mean with error bars representing SEM between
technical duplicates. Results are representative of at least two independent experiments. MFI, mean ﬂuorescence intensity; NS, no stimulation
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a powerful tool to study how the MAIT cell response progresses
during a systemic bacterial infection.
We observed that the relative frequency of circulating
MAIT cells signiﬁcantly decreased early in individuals that
developed enteric fever. This could indicate that, as early as day 4,
the MAIT cells in these individuals are responding to the pre-
sence of S. Paratyphi A in the host. This migration of MAIT cells
from circulation has been suggested previously by studies
reporting lower frequency of circulating MAIT cells in infected
patients compared with healthy individuals16,28. In addition to
this, a decrease in circulating MAIT cell frequencies was observed
in trials that administered live S. Typhi23 and live-attenuated
Shigella dysenteriae 1 vaccine17. The ﬁndings of these previous
studies are in line with our observations, and suggest that cir-
culating MAIT cells are responsive to in vivo bacterial infection
and may decrease in frequency in the blood as they move to
locally inﬂamed and infected tissues. Accumulation of MAIT cells
in infected tissues has been demonstrated by studies using lung
infection mouse models8,18. We also observed a recovery in
MAIT cell frequency following antibiotic treatment, suggesting
that MAIT cell redistribution and reduction in circulating num-
bers is reversible in bacterial infection. This observed MAIT cell
recovery is unlike the non-reversible decrease of MAIT cells that
is observed in human immunodeﬁciency virus (HIV)
infection29,30.
We show that a proportion of circulating MAIT cells in
diagnosed individuals were activated and proliferating at the peak
of infection, indicating that they were playing a role in the host
response to S. Paratyphi A. Similar observations have been made
in studies assessing MAIT cell responses in vaccination and live
infection trials17,23,24. However, the mode of activation of
MAIT cells has not been addressed in these human in vivo stu-
dies. This is an important point as in vitro studies have shown
that MAIT cells can become activated both through TCR sti-
mulation or through TCR-independent cytokine stimulation19,31,
which we also observed after in vitro S. Paratyphi A infection.
To address whether the activation we observed was due to the
MR1−TCR interaction, and thus due to the presence of bacteria-
derived ligand, we assessed the MAIT cell TCR repertoire and
found that, although the TRBV maintained oligoclonality, the
TCR repertoire had undergone reshaping and clonal contraction/
expansion at the clonotypic level during infection. This suggests
that the TCR−MR1 interaction may be inﬂuencing the circulating
MAIT cell population. There are several studies which have
indirectly provided evidence that the TCR−MR1 interaction is
important for MAIT cell responses to bacterial infection. In a
study of critically ill patients, the circulating MAIT cell propor-
tion in patients with streptococcal infections (bacteria which lack
the riboﬂavin synthesis pathway) was higher than those with
infections by bacteria which do produce riboﬂavin metabolites28.
Also, a recent study using S. enterica serovar Typhimurium in a
mouse lung infection model demonstrated that the MAIT cell
response to infection required MR1 and the ability for bacteria to
produce the riboﬂavin-derived ligand18. These results support the
concept that the riboﬂavin metabolite ligands are important for
the MAIT cell response to bacterial infection and that the changes
we observed in TCR repertoire could be driven by the riboﬂavin
metabolite antigen.
We observed an increased functional avidity of expanded
MAIT cell clonotypes to the riboﬂavin ligand compared with a
contracted clonotype from the same diagnosed individual. The
increased functional avidity could, in part, explain the selective
clonal expansion we observed in diagnosed individuals. The
concept of MAIT cell selectivity based on TCR sequence has been
suggested previously by a study assessing MAIT cell TCR
repertoire after in vitro infection14. However, this study also
suggested differences in TRBV chain usage as well as suggesting
ligand/pathogen discrimination, features which we did not
observe in our study. Our results showed that the Jurkat.MAIT
activation level differed between clonotypes, but that this acti-
vation was relatively conserved, regardless of whether they were
stimulated with S. Paratyphi A, E. coli, or different riboﬂavin
metabolites. Our observations are supported by the ﬁndings from
a MAIT TCR−MR1 structural biology study that demonstrated
that the CDR3β region directly interacts with the MAIT cell
ligand and could inﬂuence and “ﬁne-tune” the MAIT cell
response15.
It is likely that the increase in TCR functional avidity for
riboﬂavin metabolites is not exclusively the driving factor for
preferential expansion of certain MAIT clonotypes. A driving
factor, which we were not able to explore, was the cytokine-
dependent activation that we demonstrated in the in vitro S.
Paratyphi A challenge assay. Recent advances in methodology
that can couple TCR sequence with transcriptional proﬁling of
single cells32 could help elucidate this, along with other factors
that could contribute to MAIT cell clonal expansion in response
to infection.
In summary, we have determined the timing and dynamics of
the MAIT cell response to S. Paratyphi A infection. We have
clearly shown that MAIT cells undergo an adaptive clonal
response during infection, yet are still driven by their speciﬁcity to
a narrow set of vitamin metabolite antigens. These ﬁndings
demonstrate how MAIT cells sit directly at the interface between
innate and adaptive immunity and that lifetime exposure to dif-
ferent microbial infections could impact and shape the host’s
MAIT cell TCR repertoire. To understand the functional impli-
cations of this, future experiments should assess whether select
MAIT cell clonotypes that expand in response to S. Paratyphi A
infection may play a protective role in subsequent infections with
S. enterica or other bacterial species.
Methods
Participants and human infection model. The controlled human S. Paratyphi A
infection model utilized has been previously described25. Brieﬂy, adult participants
(aged 18–60) ingested a single dose of 1–5×103 colony-forming units (CFU) of S.
Paratyphi A strain NVGH308 suspended in NaHCO3 (0.53 g/30 mL) solution. The
following 14 days involved daily follow-up and blood monitoring. A diagnosis of
enteric fever was deﬁned as S. Paratyphi A bacteremia and/or persistent fever (>38
°C) lasting >12 h. Participants were treated with ciproﬂoxacin (500 mg, twice daily
for 14 days) at the time of diagnosis, or at day 14 if they remained asymptomatic
and were not diagnosed. Healthy adult blood donor controls were from laboratory
volunteers or leukocyte cones obtained from NHS blood and transplant service.
Peripheral blood mononuclear cells (PBMCs) were isolated from all blood samples
and leukocyte cones by gradient centrifugation using Lymphoprep™ (AxisShield).
Cell lines and transfection. C1R and J.RT3-T3.5 (JRT3) cell lines (ATCC) were
cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS), 1%
penicillin-streptomycin and 2 mM L-glutamine. The 293T cell line (ATCC) was
cultured in DMEM supplement with 10% FBS, 1% penicillin-streptomycin and 2
mM L-glutamine. All cell lines were tested negative for mycoplasma contamination.
The C1R.MR1 cell line was produced by cloning the MR1 gene into a pHR-
IRES-GFP vector which was then co-transfected into 293T cells with the HIV gag-
pol and VSV-G expression plasmids using FuGENE 6 Transfection Reagent
(Roche) according to the manufacturer’s instructions. The supernatant from this
culture containing the lentiviral particles was then used to transduce C1R cells that
were then sorted based on high expression of GFP. MR1 expression was then
conﬁrmed by MR1 antibody staining and ﬂow cytometry.
The Jurkat.MAIT cell lines were produced by cloning into a pHR-IRES vector
the TRAV1-2–TRAJ33 (CDR3α: CAVMDSNYQLIW) MAIT cell TCRα chain and
then cloning in the TCRβ chain of interest. The vector was then co-transfected into
293T cells with the HIV gag-pol and VSV-G expression plasmids using X-
tremeGENE™ 9 DNA Transfection Reagent (Sigma) according to the
manufacturer’s instructions. The supernatant from this culture containing the
lentiviral particles was then used to transduce JRT3 cells (which lack an
endogenous TCRβ chain). TCR expression and pairing with MAIT cell TRAV1-2
(Vα7.2) chain was conﬁrmed by ﬂow cytometry and cells sorted based on CD3 and
Vα7.2 expression.
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Preparation of bacterial stocks. All work involving S. Paratyphi A was carried out
in a CAT3 facility. S. Paratyphi A strain NVGH308 and E. coli strain DH5α were
plated on Lysogeny broth (LB) agar plates overnight at 37 °C. A single colony was
picked, plated, and incubated overnight at 37 °C to ensure single origin colony. A
single colony was chosen and grown in LB+10% sucrose overnight. LB+10%
sucrose was inoculated with the overnight culture 1:100 and grown for 3 h (to log-
phase growth point). Frozen aliquots were stored at −80 °C and thawed just prior to
use in in vitro experiments. The CFU for each bacterial stock was determined and
used for all multiplicity of infection calculations.
In vitro infection. For co-cultures, C1R.MR1 and Jurkat.MAIT cells (at a ratio of
2:1) were incubated with supernatant from an overnight bacterial culture grown in
LB. For ligand experiments, RL-6,7-DiMe (Toronto Research Chemicals) or 10 μM
methylglyoxal with 5-A-RU26 was added directly to C1R.MR1 cells. Cells were then
incubated for 18–20 h.
For PBMCs, cells were infected with live S. Paratyphi A strain NVGH308 or E.
coli strain DH5α from frozen mid-log phase stocks. After 1 h, 100 μg/mL
gentamicin was added and samples left for 16–18 h. For intracellular staining, 5 μg/
mL brefeldin A solution was then added and incubated for 6 h. Intracellular
Fixation & Permeabilization Buffer (eBioscience) was used for intracellular
staining.
For MR1 blocking experiments, 10 μg/mL anti-MR1 antibody (clone 26.5,
Biolegend) or mouse IgG2a isotype control (MOPC-173, Biolegend) were used. For
IL-12 blocking experiments, LEAF™ puriﬁed anti-human IL12/23 p40 antibody
(C11.5, Biolegend) and LEAF™ puriﬁed mouse IgG1 isotype control (MG1-45,
Biolegend) were used. Antibodies were pre-incubated for 1 h with C1R.MR1 cells
or PBMCs prior to addition of bacteria, supernatant, or ligand.
Flow cytometry and cell sorting. Antibodies for ﬂow cytometry and cell sorting
were from Biolegend unless otherwise indicated. Antibodies used were: CD161
APC (HP-3G10), CD3 PE/Cy7 (UCHT1), CD3 APC/Cy7 (HIT3a), CD38 CF594
(HIT2, BD Biosciences), CD4 Alexa Fluor® 700 (RPA-T4), CD69 Paciﬁc Blue™
(FN50), TCR γ/δ BV421™ (B1), Granzyme B PE (GB11, BD Biosciences), IFN-γ
BV786 (4S.B3, BD Biosciences), TCR Vα7.2 BV605™ or PerCP/Cy5.5 (3C10),
TNF BV650 (MAb11, BD Biosciences). Dead cells were excluded using LIVE/
DEAD® Fixable Aqua Dead Cell Stain Kit (Life Technologies). Flow cytometry data
was collected on BD LSRFortessa™ X20 or Invitrogen Attune NxT. Cell sorting
was performed on BD FACSAria™ Fusion Cell Sorter or BD FACSAria™ III. Data
was analyzed using FlowJo™ cell analysis software (FlowJo, LLC).
Tetramer staining and decay assay. The MR1 5-OP-RU and 6-formylpterin (6-
FP) PE-conjugated tetramers were provided by the NIH Tetramer Core Facility.
For staining PBMCs, cells were stained with LIVE/DEAD® Fixable Aqua Dead Cell
Stain Kit, followed by incubation with the MR1 tetramer (5 μg/mL) for 40 min at
room temperature followed by surface antibody staining for 20 min at 4 °C. For the
tetramer decay assay, Jurkat.MAIT lines were stained with LIVE/DEAD® Fixable
Aqua Dead Cell Stain Kit followed by incubation with 5-OP-RU MR1 tetramer
(2.5 μg/mL) for 40 min at room temperature. Excess tetramer was washed off and
cells re-suspended in buffer with or without 20 μg/mL anti-MR1 antibody (clone
26.5, Biolegend). Samples were left at 37 °C and periodic samples taken, washed
and ﬁxed immediately. Once all samples were collected, CD3 surface staining was
performed.
Mass cytometry sample preparation. Frozen PBMCs (2–3 million) from chal-
lenged volunteers were thawed and washed with RPMI-1640 media supplemented
with 1% FBS, 1% penicillin/streptomycin, 2 mM L-glutamine, 1% 1M HEPES and
50 μM β-mercaptoethanol. Cells were washed twice in cold PBS, and incubated on
ice with 200 μM cisplatin for 5 min. Cells were then washed with CyFACS buffer
(PBS+4% FBS+0.05% sodium azide) and stained with α-GalCer-Eu153 tetramer
(that was produced from α-GalCer monomers that were tetramerized using
streptavidin conjugated with 153Eu) for 30 min at room temperature in the pre-
sence of 10 μM free biotin. This was followed by a 30-min incubation in primary
antibody mix (Supplementary Table 1) on ice. Cells were then washed twice in
CyFACS and stained with metal-tagged surface antibodies (Supplementary
Table 2). After 30 min, the cells were washed twice with CyFACS and incubated in
Foxp3 Fixation/Permeabilization buffer (eBioscience) on ice for 30 min to enable
intranuclear staining. Cells were then washed twice in Permeabilization (perm)
buffer (Biolegend) (as this is the permeabilization buffer optimized for our CyTOF
protocol) and stained with metal-tagged intracellular/intranuclear antibodies
(Supplementary Table 3) for 30 min on ice. After washing twice in perm buffer,
cells were incubated on ice with metal-tagged streptavidin-155 for 10 min. Cells
were then washed twice in perm buffer, once in PBS, and ﬁxed in 2% paraf-
ormaldehyde (PFA) at 4 °C. The following day, cells were washed twice with perm
buffer and once with PBS.
Mass cytometry sample barcoding. We next barcoded stained samples to
eliminate doublets and be able to run multiple samples simultaneously. Cells were
incubated with cellular barcodes for 30 min as previously described33. Pt-102, Rh-
103, Pd-104, -105, -106, -108, and -110 were used for this experiment. 113 was not
used due to interference with CD57 on mass 115, based on our observations from
previous experiments. A small degree of interference was observed between 110
and 112/114 but this did not affect de-barcoding as we could easily gate on 110
positive cells without including 112/114 positive cells. In addition, since CD14-
positive cells (112 and 114 positive) were excluded for analysis, interference
between 110 and 112/114 was not an issue.
Mass cytometry sample batching and acquisition. Cells were then washed once
with perm buffer and incubated in CyFACS for 10 min on ice. Cellular DNA was
labeled at room temperature with 250 nM iridium interchelator (Fluidigm) diluted
in PBS with 2% PFA. After cellular DNA labeling cells were washed twice with
CyFACS and kept in a 96-well U-bottom plate.
To accommodate the required numbers of samples, two barcoded batches were
prepared, ensuring each batch included all time-points for a given volunteer. A
single healthy donor’s PBMCs, that was prepared and stained in parallel with
volunteer samples, was included in each batch as a control for batch-to-batch
variation.
For acquisition, small aliquots of cells from each batch were ﬁltered through a
0.35 μM cell strainer into a 5 mL polystyrene tube. The batch aliquot was then
washed twice in water before being resuspended in water at 500,000 cells/mL.
EQ Four Element Calibration Beads (Fluidigm) were added at a ﬁnal concentration
of 1% prior to sample acquisition. The same pooling steps were repeated each
time the acquisition of an aliquoted batch was completed. This approach was
taken to minimize the duration the stained cells were kept in water (1–2 h
maximum).
Both batches of samples were acquired on subsequent days to minimize batch
effects which can occur if stained cells are stored in CyFACS long term. Batch effect
was analyzed by performing a tSNE plot to compare the PBMCs from the healthy
donor stained and acquired with the two distinct batches. Cells acquisition was
performed on a CyTOF2 (Fluidigm) and the total number of live cells acquired for
each sample was between 30,000 and 100,000.
Mass cytometry data analysis. After mass cytometry acquisition, the data was
exported in ﬂow cytometry ﬁle format, normalized34 and events with parameters
having zero values were randomized using a uniform distribution of values between
−1 and 0. Each sample containing a unique combination of two metal barcodes was
Table 2 Primers for TCR repertoire ampliﬁcation
PRIMER NAME PRIMER SEQUENCE (5′–3′) USE
AC1R_RV ACACATCAGAATCCTTACTTTG TCRα
AC2R_RV TACACGGCAGGGTCAGGGT TCRα
BC1R_RV CAGTATCTGGAGTCATTGA TCRβ
BC2R_RV TGCTTCTGATGGCTCAAACAC TCRβ
HUM_ACJ_RV NNNN(XXXXX)GGGTCAGGGTTCTGGATAT TCRα
HUM_BCJ_RV NNNN(XXXXX)ACACSTTKTTCAGGTCCTC TCRβ
HUM_STEP1_FW NNNN(XXXXX)CACTCTATCCGACAAGCAGT TCRα/β
SMART20_FW CACTCTATCCGACAAGCAGTGGTATCAACGCAG TCRβ
SMARTTRAV1-2_FW CACTCTATCCGACAAGCAGTCAGCAACATGCTGGCGAAGC TCRα
SWITCH_OLIGO AAGCAGTGGTATCAACGCAGAGTACTCTT(rG)3 TCRβ
TRAV1-2_FW CAGCAACATGCTGGCGAAGC TCRα
XXXXX indicates unique barcoded sequence used for identifying individual samples after pooling. Primers sequences based on those previously published35
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de-convoluted using manual gating in FlowJo to select cells stained with two (and
only two) barcoding channels. MAIT cells were identiﬁed as CD14− CD19− CD3+
Vα7.2+ CD161+ and marker expression assessed using Cytobank (MRC) software.
The total number of MAIT cells identiﬁed in each sample ranged from 83 to 346.
Flow cytometry for validating mass cytometry experiments. Samples used for
mass cytometry validation were 200 μL of whole blood that were ﬁxed in 1-step
Fix/Lyse Solution (eBioscience), and stored at −80 °C. Fixed cells were thawed,
permeabilized using Permeabilization Buffer (eBioscience) and then stained with
the following antibodies speciﬁc for epitopes insensitive to ﬁxation, purchased from
Biolegend unless otherwise indicated: CD38 BB515 (HIT2, BD Biosciences), CD4
BV510™ (SK3), CD8 PerCP/Cy5.5 (HIT8a), CD161 APC (HP-3G10, eBioscience),
HLA-DR APC/Cy7 (L243), TCR Vα7.2 BV605™ (3C10), TCR γ/δ BV421™ (B1),
Ki67 PE (Ki-67), and CD3 BV650™ (UCHT1).
Activation assay for assessing dialyzed FBS. 100,000 CD4+ T cells speciﬁc for
the S. enterica protein CdtB were stimulated with 3 μg/mL CdtB 105–125 peptide
for 18 h in culture media containing either normal or dialyzed FBS (Gibco). Cells
were then stained for ﬂow cytometry using anti-CD69 (A488)-conjugated antibody.
TCRβ repertoire library preparation. Cells for TCR repertoire analysis were
sorted directly into lysis buffer from RNAqueous®-Micro Total RNA Isolation Kit
(Ambion). Sorted cell numbers ranged from 5000 to 10,000 cells per sample. RNA
was then extracted using the RNAqueous®-Micro Total RNA Isolation Kit fol-
lowing the manufacturer’s instructions. The unbiased TCR ampliﬁcation method
was used as previously described35. Brieﬂy, template-switch cDNA was produced
using SMARTScribe™ Reverse Transcriptase (Clontech) with switch_oligo and
BC1R primers described in Table 2. First and second PCR steps were conducted
using Phusion® High-Fidelity DNA Polymerase (New England Biolabs) and pri-
mers described in Table 2. Samples were pooled and NEBNext® Ultra™ DNA
Library Prep Kit for Illumina® (New England Biolabs) was used following the
manufacturer’s instructions. Samples were sequenced on Illumina MiSeq platform
using MiSeq reagent kit V2 300 cycle (Illumina).
TCRα repertoire library preparation. cDNA was synthesized using the oligo-dT
primer method of the RETROscript® Kit (Ambion) following the manufacturer’s
instructions. The TCRα chain was ampliﬁed by PCR using Phusion® master mix
and primers speciﬁc for TRAV1-2 (TRAV1-2_FW) and the TRAC region
(AC1R_RV) primer details outlined in Table 2. The PCR products were used for a
second nested PCR using primers Smart_TRAV1-2_FW and AC2R_RV. PCR
product was used as a template for a third nested PCR using primers Step_1_FW
and Hum_bcj_RV containing a barcoded sequence. Samples were then pooled for
MiSeq analysis as described in TCRβ library preparation.
TCR repertoire analysis. The sequencing ﬁles generated by the MiSeq were split
based on their barcoded sequence using Jemultiplexer (GBCS) and then run
through the MiTCR software36, aligning TCRα/β sequences using default para-
meters. VDJ Tools37 was then used to ﬁlter out the non-functional sequences prior
to post-analysis visualization. Clonotypes were deﬁned based on their amino acid
sequence. Frequencies were determined by number of assigned sequence reads.
Default strict sample intersection rules were applied to VDJ tools analysis.
Statistical analysis. Statistical analysis was performed using Prism software
(Graphpad). For multiple comparisons, one-way ANOVA was used with Dunnett’s
test to correct for multiple comparisons. For comparison between two groups,
either Student’s paired two-tailed t-test or unpaired two-tailed t-test was used.
Signiﬁcant result is indicated where *P< 0.05, **P< 0.01, ***P< 0.001, ****P<
0.0001. Sample sizes were limited by the availability of volunteer samples but
adequate to detect differences between sample groups, as indicated by the repro-
ducibility and variability of each experiment.
Ethics. Written informed consent was obtained for all study volunteers in accor-
dance with the Declaration of Helsinki and ethical approval was received from
Oxford Research Ethics Committee (14/SC/0004 and 14/SC/1204). Samples
obtained from the controlled human S. Paratyphi A infection model were part of
registered clinical trials (NCT02100397 and NCT02192008) and conformed to the
Good Clinical Practice (GCP) guidelines.
Data availability. Sequence data that support the ﬁndings of this study have been
deposited in NCBI Sequence Read Archive with the primary accession code
PRJNA412739.
Received: 24 May 2017 Accepted: 7 December 2017
References
1. Howson, L. J., Salio, M. & Cerundolo, V. MR1-restricted mucosal-associated
invariant T cells and their activation during infectious diseases. Front.
Immunol. 6, 303 (2015).
2. Kjer-Nielsen, L. et al. MR1 presents microbial vitamin B metabolites to
MAIT cells. Nature 491, 717–723 (2012).
3. Dusseaux, M. et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted,
CD161hi IL-17-secreting T cells. Blood 117, 1250–1259 (2011).
4. Gold, M. C. et al. Human mucosal associated invariant T cells detect bacterially
infected cells. PLoS Biol. 8, e1000407 (2010).
5. Tilloy, F. et al. An invariant T cell receptor alpha chain deﬁnes a novel TAP-
independent major histocompatibility complex class Ib-restricted alpha/beta T
cell subpopulation in mammals. J. Exp. Med. 189, 1907–1921 (1999).
6. Treiner, E. et al. Mucosal-associated invariant T (MAIT) cells: an evolutionarily
conserved T cell subset. Microbes Infect. 7, 552–559 (2005).
7. Tsukamoto, K., Deakin, J. E., Graves, J. A. M. & Hashimoto, K. Exceptionally
high conservation of the MHC class I-related gene, MR1, among mammals.
Immunogenetics 65, 115–124 (2013).
8. Meierovics, A., Yankelevich, W. J. C. & Cowley, S. C. MAIT cells are critical for
optimal mucosal immune responses during in vivo pulmonary bacterial
infection. Proc. Natl. Acad. Sci. USA 110, E3119–E3128 (2013).
9. Georgel, P., Radosavljevic, M., Macquin, C. & Bahram, S. The non-conventional
MHC class I MR1 molecule controls infection by Klebsiella pneumoniae in
mice. Mol. Immunol. 48, 769–775 (2011).
10. Chua, W. J. et al. Polyclonal mucosa-associated invariant T cells have unique
innate functions in bacterial infection. Infect. Immun. 80, 3256–3267 (2012).
11. Reantragoon, R. et al. Antigen-loaded MR1 tetramers deﬁne T cell receptor
heterogeneity in mucosal-associated invariant T cells. J. Exp. Med. 210,
2305–2320 (2013).
12. Lepore, M. et al. Parallel T-cell cloning and deep sequencing of human
MAIT cells reveal stable oligoclonal TCRbeta repertoire. Nat. Commun. 5, 3866
(2014).
13. Gherardin, N. A. et al. Diversity of T cells restricted by the MHC class I-related
molecule MR1 facilitates differential antigen recognition. Immunity 44, 32–45
(2016).
14. Gold, M. C. et al. MR1-restricted MAIT cells display ligand discrimination and
pathogen selectivity through distinct T cell receptor usage. J. Exp. Med. 211,
1601–1610 (2014).
15. Eckle, S. B. et al. A molecular basis underpinning the T cell receptor
heterogeneity of mucosal-associated invariant T cells. J. Exp. Med. 211,
1585–1600 (2014).
16. Le Bourhis, L. et al. Antimicrobial activity of mucosal-associated invariant
T cells. Nat. Immunol. 11, 701–708 (2010).
17. Le Bourhis, L. et al. MAIT cells detect and efﬁciently lyse bacterially-infected
epithelial cells. PLoS Pathog. 9, e1003681 (2013).
18. Chen, Z. et al. Mucosal-associated invariant T-cell activation and accumulation
after in vivo infection depends on microbial riboﬂavin synthesis and co-
stimulatory signals. Mucosal Immunol. 10, 58–68 (2017).
19. Ussher, J. E. et al. CD161++ CD8+ T cells, including the MAIT cell subset, are
speciﬁcally activated by IL-12+ IL-18 in a TCR-independent manner. Eur. J.
Immunol. 44, 195–203 (2014).
20. Kurioka, A. et al. MAIT cells are licensed through granzyme exchange to kill
bacterially sensitized targets. Mucosal Immunol. 8, 429–440 (2014).
21. Leung, D. T. et al. Circulating mucosal associated invariant T cells are activated
in Vibrio cholerae O1 infection and associated with lipopolysaccharide
antibody responses. PLoS Negl. Trop. Dis. 8, e3076 (2014).
22. Booth, J. S. et al. Mucosal-associated invariant T cells in the human gastric
mucosa and blood: role in Helicobacter pylori infection. Front. Immunol. 6, 466
(2015).
23. Salerno-Goncalves, R. et al. Challenge of humans with wild-type Salmonella
enterica Serovar Typhi elicits changes in the activation and homing
characteristics of mucosal-associated invariant T cells. Front. Immunol. 8, 398
(2017).
24. Greene, J. M. et al. MR1-restricted mucosal-associated invariant T (MAIT) cells
respond to mycobacterial vaccination and infection in nonhuman primates.
Mucosal Immunol. 10, 802–813 (2016).
25. Dobinson, H. C. et al. Evaluation of the clinical and microbiological response to
Salmonella Paratyphi A infection in the ﬁrst paratyphoid human challenge
model. Clin. Infect. Dis. 64, 1066–1073 (2017).
26. Corbett, A. J. et al. T-cell activation by transitory neo-antigens derived from
distinct microbial pathways. Nature 509, 361–365 (2014).
27. Leeansyah, E. et al. Activation, exhaustion, and persistent decline of the
antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1
infection. Blood 121, 1124–1135 (2013).
28. Grimaldi, D. et al. Speciﬁc MAIT cell behaviour among innate-like T
lymphocytes in critically ill patients with severe infections. Intensive Care Med.
40, 192–201 (2014).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02540-x
10 NATURE COMMUNICATIONS |  (2018) 9:253 |DOI: 10.1038/s41467-017-02540-x |www.nature.com/naturecommunications
29. Cosgrove, C. et al. Early and nonreversible decrease of CD161++/MAIT cells in
HIV infection. Blood 121, 951–961 (2013).
30. Fernandez, C. S. et al. MAIT cells are depleted early but retain functional
cytokine expression in HIV infection. Immunol. Cell Biol. 93, 177–188 (2014).
31. van Wilgenburg, B. et al. MAIT cells are activated during human viral
infections. Nat. Commun. 7, 11653 (2016).
32. Eltahla, A. A. et al. Linking the T cell receptor to the single cell transcriptome in
antigen-speciﬁc human T cells. Immunol. Cell Biol. 94, 604–611 (2016).
33. Wong Michael, T. et al. Mapping the diversity of follicular helper T cells in
human blood and tonsils using high-dimensional mass cytometry analysis. Cell
Rep. 11, 1822–1833 (2015).
34. Finck, R. et al. Normalization of mass cytometry data with bead standards.
Cytom. A 83, 483–494 (2013).
35. Mamedov, I. Z. et al. Preparing unbiased T-cell receptor and antibody cDNA
libraries for the deep next generation sequencing proﬁling. Front. Immunol. 4,
456 (2013).
36. Bolotin, D. A. et al. MiTCR: software for T-cell receptor sequencing data
analysis. Nat. Methods 10, 813–814 (2013).
37. Shugay, M. et al. VDJtools: unifying post-analysis of T cell receptor repertoires.
PLoS Comput. Biol. 11, e1004503 (2015).
Acknowledgements
We would like to thank the study volunteers. Thank you to Rosanna McEwen-Smith,
Victoria Woodcock, and Andreas V. Hadjinicolaou for assistance with blood collection,
Craig Waugh for assistance with cell sorting, Tim Rostron for assistance with next-
generation sequencing, Mike Stubbington for reading and editing the manuscript and
Hashem Koohy for assistance with statistical analysis. The MR1 tetramer technology was
developed jointly by James McCluskey, Jamie Rossjohn, and David Fairlie, and the
material was produced by the NIH Tetramer Core Facility as permitted to be distributed
by the University of Melbourne. This work was supported by the UK Medical Research
Council (MRC) (MR/K021222/1), Cancer Research UK (CRUK) (C399/A2291), the
Oxford National Institute for Health Research (NIHR) Biomedical Research Centre, the
Bill & Melinda Gates Foundation (OPP1084259), the European Vaccine Initiative (PIM)
and core funding from the Singapore Immunology Network (SIgN) and the SIgN
immunomonitoring platform. G.S.B. acknowledges support in the form of a Personal
Research Chair from Mr. James Bardrick and the UK MRC (MR/K012118/1).
Author contributions
L.J.H. conceived and designed the study, processed the samples, performed the
experiments, analyzed the data, and wrote the manuscript. G.N. conceived and designed
the study, processed the samples, performed the ﬂow cytometry experiments, analyzed
the data, and edited the manuscript. D.S. designed and performed cellular assay
experiments. H.G. conceived and designed TCR repertoire experiments. P.K. processed
the samples and performed the ﬂow cytometry experiments. M.R. designed and con-
ducted cell sorting experiments. L.P.-L. conceived the in vitro infection model and
provided bacteria handling training. K.W.W.T. and E.W.N. performed the mass cyto-
metry experiments. H.C.D., M.M.G. and A.J.P. conceived the human challenge model,
obtained funding, and directed the clinical trial and sampling. N.V. and G.S.B. synthe-
sized the 5-A-RU compound. V.C. conceived and designed the study, edited the
manuscript and supervised the experiments. All authors discussed the results and
commented on the manuscript.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
017-02540-x.
Competing interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2018
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02540-x ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:253 |DOI: 10.1038/s41467-017-02540-x |www.nature.com/naturecommunications 11
